Casimersen, Exon 45 Skipping Duchenne Therapy, Under FDA Priority Review
News
An application requesting the approval of casimersen (SRP-4045) to treat Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping has been accepted and placed under priority review by the U.S. Food and Drug ... Read more